Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

JYNT vs DBVT vs ALKS vs XPOF

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
JYNT
The Joint Corp.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-89.0%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-61.6%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+36.8%
XPOF
Xponential Fitness, Inc.

Leisure

Consumer CyclicalNYSE • US
Market Cap$244M
5Y Perf.-44.2%

JYNT vs DBVT vs ALKS vs XPOF — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
JYNT logoJYNT
DBVT logoDBVT
ALKS logoALKS
XPOF logoXPOF
IndustryMedical - Care FacilitiesBiotechnologyBiotechnologyLeisure
Market Cap$124M$1712.35T$5.90B$244M
Revenue (TTM)$57M$0.00$1.56B$299M
Net Income (TTM)$3M$-168M$153M$-34M
Gross Margin78.5%65.4%83.2%
Operating Margin1.1%12.3%7.8%
Forward P/E44.9x24.8x10.9x
Total Debt$2M$22M$70M$525M
Cash & Equiv.$24M$194M$1.12B$46M

JYNT vs DBVT vs ALKS vs XPOFLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

JYNT
DBVT
ALKS
XPOF
StockJul 21May 26Return
The Joint Corp. (JYNT)10011.0-89.0%
DBV Technologies S.… (DBVT)10038.4-61.6%
Alkermes plc (ALKS)100136.8+36.8%
Xponential Fitness,… (XPOF)10055.8-44.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: JYNT vs DBVT vs ALKS vs XPOF

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JYNT and ALKS are tied at the top with 2 categories each — the right choice depends on your priorities. Alkermes plc is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. XPOF and DBVT also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
JYNT
The Joint Corp.
The Growth Play

JYNT has the current edge in this matchup, primarily because of its strength in growth exposure and defensive.

  • Rev growth 5.2%, EPS growth 133.9%, 3Y rev CAGR -18.5%
  • Beta 0.98, current ratio 1.59x
  • 5.2% revenue growth vs DBVT's -100.0%
  • Beta 0.98 vs XPOF's 1.94
Best for: growth exposure and defensive
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +110.4% vs XPOF's -22.6%
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.

  • -11.0% 10Y total return vs JYNT's 191.9%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs XPOF's -11.3%
  • 5.4% ROA vs DBVT's -89.0%
Best for: long-term compounding and sleep-well-at-night
XPOF
Xponential Fitness, Inc.
The Value Play

XPOF is the clearest fit if your priority is value and dividends.

  • Lower P/E (10.9x vs 24.8x)
  • 2.5% yield; the other 3 pay no meaningful dividend
Best for: value and dividends
See the full category breakdown
CategoryWinnerWhy
GrowthJYNT logoJYNT5.2% revenue growth vs DBVT's -100.0%
ValueXPOF logoXPOFLower P/E (10.9x vs 24.8x)
Quality / MarginsALKS logoALKS9.8% margin vs XPOF's -11.3%
Stability / SafetyJYNT logoJYNTBeta 0.98 vs XPOF's 1.94
DividendsXPOF logoXPOF2.5% yield; the other 3 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs XPOF's -22.6%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

JYNT vs DBVT vs ALKS vs XPOF — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

JYNTThe Joint Corp.
FY 2025
Royalty
60.5%$33M
Advertising
19.0%$10M
Technology Service
11.0%$6M
Franchise
6.1%$3M
Product and Service, Other
3.3%$2M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
XPOFXponential Fitness, Inc.
FY 2025
Franchise
50.7%$193M
Product
11.2%$42M
Franchise Marketing Fund Revenue
9.6%$36M
Equipment Revenue
9.2%$35M
Service, Other
7.1%$27M
Merchandise Revenue
6.3%$24M
Franchise And Service Revenue
5.9%$22M

JYNT vs DBVT vs ALKS vs XPOF — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGJYNT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to XPOF's -11.3%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
RevenueTrailing 12 months$57M$0$1.6B$299M
EBITDAEarnings before interest/tax$2M-$112M$212M$35M
Net IncomeAfter-tax profit$3M-$168M$153M-$34M
Free Cash FlowCash after capex$3M-$151M$392M-$3M
Gross MarginGross profit ÷ Revenue+78.5%+65.4%+83.2%
Operating MarginEBIT ÷ Revenue+1.1%+12.3%+7.8%
Net MarginNet income ÷ Revenue+5.7%+9.8%-11.3%
FCF MarginFCF ÷ Revenue+4.7%+25.1%-1.1%
Rev. Growth (YoY)Latest quarter vs prior year+13.3%+28.2%-21.0%
EPS Growth (YoY)Latest quarter vs prior year+71.4%+91.5%-4.1%+79.1%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

XPOF leads this category, winning 5 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 46% valuation discount to JYNT's 45.6x P/E. On an enterprise value basis, XPOF's 7.9x EV/EBITDA is more attractive than JYNT's 126.9x.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
Market CapShares × price$124M$1712.35T$5.9B$244M
Enterprise ValueMkt cap + debt − cash$103M$1712.35T$4.9B$723M
Trailing P/EPrice ÷ TTM EPS45.63x-0.76x24.76x-4.45x
Forward P/EPrice ÷ next-FY EPS est.44.85x10.90x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple126.93x17.25x7.89x
Price / SalesMarket cap ÷ Revenue2.26x4.00x0.78x
Price / BookPrice ÷ Book value/share8.70x0.66x3.28x
Price / FCFMarket cap ÷ FCF370.99x12.28x9.86x
XPOF leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 5 of 9 comparable metrics.

JYNT delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to JYNT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
ROE (TTM)Return on equity+16.9%-130.2%+8.8%
ROA (TTM)Return on assets+5.0%-89.0%+5.4%-9.5%
ROICReturn on invested capital+18.9%+75.0%
ROCEReturn on capital employed-2.9%-145.7%+14.2%+30.3%
Piotroski ScoreFundamental quality 0–96475
Debt / EquityFinancial leverage0.13x0.13x0.04x
Net DebtTotal debt minus cash-$22M-$172M-$1.0B$479M
Cash & Equiv.Liquid assets$24M$194M$1.1B$46M
Total DebtShort + long-term debt$2M$22M$70M$525M
Interest CoverageEBIT ÷ Interest expense-189.82x32.30x-0.24x
ALKS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $1,608 for JYNT. Over the past 12 months, DBVT leads with a +110.4% total return vs XPOF's -22.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs XPOF's -39.1% — a key indicator of consistent wealth creation.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
YTD ReturnYear-to-date-2.0%+4.9%+25.3%-18.5%
1-Year ReturnPast 12 months-12.8%+110.4%+16.5%-22.6%
3-Year ReturnCumulative with dividends-41.0%+19.7%+14.5%-77.4%
5-Year ReturnCumulative with dividends-83.9%-69.1%+60.9%-46.6%
10-Year ReturnCumulative with dividends+191.9%-87.0%-11.0%-46.6%
CAGR (3Y)Annualised 3-year return-16.1%+6.2%+4.6%-39.1%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — JYNT and ALKS each lead in 1 of 2 comparable metrics.

JYNT is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than XPOF's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs XPOF's 58.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
Beta (5Y)Sensitivity to S&P 5000.98x1.26x1.06x1.94x
52-Week HighHighest price in past year$13.47$26.18$36.60$11.14
52-Week LowLowest price in past year$7.50$7.53$25.17$3.83
% of 52W HighCurrent price vs 52-week peak+64.4%+76.3%+96.7%+58.7%
RSI (14)Momentum oscillator 0–10049.348.160.248.4
Avg Volume (50D)Average daily shares traded57K252K2.3M626K
Evenly matched — JYNT and ALKS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: JYNT as "Buy", DBVT as "Buy", ALKS as "Buy", XPOF as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.3% for XPOF (target: $8). XPOF is the only dividend payer here at 2.50% yield — a key consideration for income-focused portfolios.

MetricJYNT logoJYNTThe Joint Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcXPOF logoXPOFXponential Fitnes…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$20.00$46.33$44.00$8.00
# AnalystsCovering analysts8152814
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises000
Dividend / ShareAnnual DPS$0.16
Buyback YieldShare repurchases ÷ mkt cap+9.1%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XPOF leads in 1 (Valuation Metrics). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

JYNT vs DBVT vs ALKS vs XPOF: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is JYNT or DBVT or ALKS or XPOF a better buy right now?

For growth investors, The Joint Corp.

(JYNT) is the stronger pick with 5. 2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate The Joint Corp. (JYNT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — JYNT or DBVT or ALKS or XPOF?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus The Joint Corp. at 45. 6x. On forward P/E, Xponential Fitness, Inc. is actually cheaper at 10. 9x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — JYNT or DBVT or ALKS or XPOF?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -83. 9% for The Joint Corp. (JYNT). Over 10 years, the gap is even starker: JYNT returned +191. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — JYNT or DBVT or ALKS or XPOF?

By beta (market sensitivity over 5 years), The Joint Corp.

(JYNT) is the lower-risk stock at 0. 98β versus Xponential Fitness, Inc. 's 1. 94β — meaning XPOF is approximately 97% more volatile than JYNT relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for The Joint Corp. — giving it more financial flexibility in a downturn.

05

Which is growing faster — JYNT or DBVT or ALKS or XPOF?

By revenue growth (latest reported year), The Joint Corp.

(JYNT) is pulling ahead at 5. 2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: The Joint Corp. grew EPS 133. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — JYNT or DBVT or ALKS or XPOF?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -10. 7% for Xponential Fitness, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -1. 6% for JYNT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is JYNT or DBVT or ALKS or XPOF more undervalued right now?

On forward earnings alone, Xponential Fitness, Inc.

(XPOF) trades at 10. 9x forward P/E versus 44. 9x for The Joint Corp. — 34. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — JYNT or DBVT or ALKS or XPOF?

In this comparison, XPOF (2.

5% yield) pays a dividend. JYNT, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is JYNT or DBVT or ALKS or XPOF better for a retirement portfolio?

For long-horizon retirement investors, The Joint Corp.

(JYNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +191. 9% 10Y return). Xponential Fitness, Inc. (XPOF) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JYNT: +191. 9%, XPOF: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between JYNT and DBVT and ALKS and XPOF?

These companies operate in different sectors (JYNT (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and XPOF (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

XPOF pays a dividend while JYNT, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

JYNT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Net Margin > 5%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

XPOF

Income & Dividend Stock

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 49%
  • Dividend Yield > 1.0%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.